NHS Lothian
Edinburgh, United Kingdom
NCT Number: NCT04591574
On discharge from intensive care (ICU) patients are often severely anaemic (have a low level of haemoglobin (Hb) in their red blood cells (RBC)). Anaemia can persist for many months making patients feel tired and fatigued. Regaining pre-illness health and energy levels can take a long time.
The ABC Post Intensive Care Trial will be the first trial to investigate if an anaemic ICU patient's health can be improved by treating with RBC transfusions following ICU discharge. We will compare the current approach as per national guidelines (restrictive transfusion), with a more active transfusion regime to correct anaemia from ICU discharge to hospital discharge.
The trial will take place in acute hospitals throughout the UK where patients are discharged after a period of time in ICU.
Patients discharged, or ready for discharge from ICU will be approached to consider participation in the trial. Once Hb level drops below 94g/L they would become eligible for inclusion (subject to meeting inclusion/exclusion criteria). The main indication for being excluded from participating in the trial is that transfusions are contraindicated (not appropriate for the patient) or they have an objection to blood transfusions.
Group allocation will be randomly assigned at ICU discharge. We will explore which patients benefit most from transfusions and those who gain no benefit.
Patients will have their Hb level checked at least weekly whilst in hospital and based on the result will have RBC transfusions as required according to the treatment regime they were randomised to.
Part of the research is based on self-reported quality of life so participants will be asked to complete a number of questionnaires at set time-points from randomisation to 6 months post randomisation.
Each participant will be actively on trial for approximately 6 months. The five-year follow will be done using routinely collected data from national databases.
This study is active but is not currently recruiting participants.
16 year and older
All sexes
Interventional
Not applicable
Edinburgh, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will receive RBC transfusions in accordance with trial protocol (intervention group) or usual care, which is in accordance with the NICE guidelines
Time frame: 3 months post randomisation
Time frame: 6 months post randomisation
Time frame: 6 months post randomisation
Time frame: 6 months post randomisation
Time frame: 3 months post randomisation
Time frame: 6 months post randomisation
Time frame: 5 years post randomisation
Time frame: 1 month post randomisation
Time frame: Variable according to patient's length of hospital stay
Time frame: 6 months post randomisation
Time frame: 6 months post randomisation
Time frame: 5 years post randomisation
Time frame: Throughout the study, for an average of 1 month
Proportion of participants compliant with the study intervention as per protocol (%).
Time frame: Throughout the study, for an average of 1 month
Time frame: 3 months post randomisation
Time frame: 3 months post randomisation
Time frame: 3 months post randomisation
Time frame: 3 months post randomisation
University of Edinburgh
Other
Anaemia Management With Red Blood Cell Transfusion to Improve Post-intensive Care Disability: a Randomised Controlled Trial (The ABC Post-intensive Care Trial)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03768830
Anxiety Disorders, Autoimmune Diseases
Rijeka, Croatia
View Trial DetailsNCT03222596
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Rijeka, Primorje-Gorski Kotar County, Croatia
View Trial DetailsNCT04565769
Anxiety Disorders, Behavior
Aarhus, Denmark
View Trial DetailsNCT07669506
Breast Diseases, Breast Neoplasms
Srikakulam, Andhra Pradesh, India
View Trial Details